RSP Systems A/S
RSP Systems awarded EUR2.4 million grant for GlucoBeam(R) by the European Union’s Horizon 2020 framework
DGAP-News: RSP Systems A/S / Key word(s): Miscellaneous RSP Systems awarded EUR2.4 million grant for GlucoBeam(R) by the European Union’s Horizon 2020 framework GlucoBeam(R) – the world’s first accurate non-invasive blood glucose measurement technology Odense, Denmark, 03 November 2016 – RSP Systems (“RSP”), the non-invasive human diagnostics company, announced today that it has been awarded a EUR2.4 million grant. The grant is part of the European Union’s Horizon 2020 framework for research and innovation. The funds will be used to take GlucoBeam(R), the world’s first accurate, non-invasive glucose monitor for diabetic patients, through to market launch. The technology is based on RSP’s proprietary and clinically validated technology, Critical Depth Raman Spectroscopy. This EUR2.4 million of funding follow swiftly on the heels of RSP’s Series A round in July of EUR4.6 million that included leading business strategist Roland Berger together with existing investors. GlucoBeam(R) has successfully been developed using Raman spectroscopy for glucose measurement in living tissue. The spectroscopic technique is commonly used in chemistry to provide a fingerprint by which molecules can be identified. Previous efforts to develop diagnostics for interstitial glucose in the skin were unsuccessful until RSP produced unequivocal evidence that by selecting a specific skin depth, results could be correlated with blood glucose levels. Today, RSP is integrating the technology into a non-invasive consumer glucose monitor with an analytical quality on par with current standards for invasive continuous glucose monitoring technologies. This integration is an industry first and will provide a truly non-invasive glucose monitor for diabetic patients. “This vital grant will help to overcome the biggest issue in glucose monitoring: compliance. For patients to finally be able to measure their glucose levels using the non-invasive GlucoBeam(R) will be a real breath of fresh air,” said Dr Anders Weber, CEO of RSP Systems A/S. “With the completion of a commercial product aided by Horizon 2020, we can now identify the best path to the best partners to make GlucoBeam(R) broadly available to patients in the European and later global markets.” Stefan Ovesen Banke, founder and CTO of RSP Systems A/S, noted: “This grant is our reward for consistently focusing on the fundamental challenges of applying Raman Spectroscopy for the quantitation of analytes in living tissue. The last leg of the journey is to productize our GlucoBeam(R) prototype for market introduction as soon as possible. The Horizon grant is both a great facilitator to achieve our goals and, due to the strict selection process we have undergone, a strong endorsement of our company and technology.” -End- For further information please contact: RSP Systems A/S Anders Weber, CEO Tel: +45 3150 0701 RSP Systems is a Danish biotechnology company founded in 2001 as a spinout from Odense University focused on using Raman spectroscopy for human diagnostics. Raman is a well-understood and widely- applied technology, but its employment for human diagnostics has long eluded industry. RSP Systems has now overcome the development hurdles and offers the world’s first robust diagnostic system. Over the past 6 years the company has focused on glucose monitoring and has now developed a prototype which shows target performance in clinical studies on diabetic patients. The company is now integrating its technology into GlucoBeam(R), a consumer device as the first non-invasive glucose monitor of analytical quality for diabetic patients. Other applications will follow GlucoBeam’s(R) market launch. Please visit: www.RSPsystems.com
2016-11-03 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |